Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berchuck

Showing results (431-440 of 683) with videos related to

Pageof 69
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromesJosé G Guillem, William C Wood, Jeffrey F Moley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancerHolly K Dressman, Andrew Berchuck, Gina Chan, et al.
Gynecologic Oncology Reports|June 16, 2025
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancersStéphanie L Gaillard, Gloria Broadwater, Andrew Berchuck, et al.
Frontiers in Genetics|March 31, 2012
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian CarcinomaLinda E Kelemen, Qinggang Wang, Irina Dinu, et al.
European Journal of Gynaecological Oncology|February 24, 2001
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGOP Bösze, R C Bast, A Berchuck, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Homologous recombination deficiency in ovarian high-grade serous carcinoma by self-reported raceKatherine A Lawson-Michod, Courtney E Johnson, Mollie E Barnard, et al.
International Journal of Cancer|September 25, 2020
Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analysesJue-Sheng Ong, Eske M Derks, Mikael Eriksson, et al.
The Oncologist|August 13, 2022
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor BoardMichelle F Green, Catherine H Watson, Sarah Tait, et al.
Nature Medicine|October 24, 2006
Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Nature Medicine|January 11, 2011
Retraction: Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Pageof 69

Showing results (431-440 of 683) with videos related to

Sort By:
Pageof 69
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromesJosé G Guillem, William C Wood, Jeffrey F Moley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancerHolly K Dressman, Andrew Berchuck, Gina Chan, et al.
Gynecologic Oncology Reports|June 16, 2025
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancersStéphanie L Gaillard, Gloria Broadwater, Andrew Berchuck, et al.
Frontiers in Genetics|March 31, 2012
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian CarcinomaLinda E Kelemen, Qinggang Wang, Irina Dinu, et al.
European Journal of Gynaecological Oncology|February 24, 2001
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGOP Bösze, R C Bast, A Berchuck, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Homologous recombination deficiency in ovarian high-grade serous carcinoma by self-reported raceKatherine A Lawson-Michod, Courtney E Johnson, Mollie E Barnard, et al.
International Journal of Cancer|September 25, 2020
Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analysesJue-Sheng Ong, Eske M Derks, Mikael Eriksson, et al.
The Oncologist|August 13, 2022
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor BoardMichelle F Green, Catherine H Watson, Sarah Tait, et al.
Nature Medicine|October 24, 2006
Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Nature Medicine|January 11, 2011
Retraction: Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, et al.
Pageof 69